Vor Biopharma (NYSE:VOR) Given Buy Rating at HC Wainwright

Vor Biopharma (NYSE:VOR)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $17.50 price target on the stock.

A number of other research firms have also commented on VOR. Barclays decreased their price objective on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating for the company in a research note on Wednesday, August 14th. JMP Securities reaffirmed a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research note on Friday, September 6th. Finally, Robert W. Baird decreased their target price on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vor Biopharma has an average rating of “Buy” and a consensus price target of $11.36.

Vor Biopharma Stock Up 14.9 %

Vor Biopharma stock opened at $0.96 on Friday. The company has a 50 day moving average price of $0.80 and a 200 day moving average price of $1.07. Vor Biopharma has a 52 week low of $0.63 and a 52 week high of $3.14.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, hitting analysts’ consensus estimates of ($0.41). Research analysts predict that Vor Biopharma will post -1.51 earnings per share for the current year.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Vor Biopharma by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock valued at $4,297,000 after purchasing an additional 69,436 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after purchasing an additional 160,642 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Vor Biopharma by 40.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock valued at $116,000 after purchasing an additional 48,017 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Vor Biopharma by 51.4% during the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock valued at $79,000 after purchasing an additional 27,597 shares in the last quarter. Finally, Rosalind Advisors Inc. bought a new position in shares of Vor Biopharma during the 3rd quarter valued at $54,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.